Overview: Hexosaminidase B Activity TestIntroduction: The Hexosaminidase B Activity Test measures hexosaminidase B activity to diagnose Sandhoff disease, causing neurological decline or seizures, helping confirm the condition. Affecting 1 in 1,000,000 people, Sandhoff disease poses diagnostic challenges due to its rarity. Following 2023 American College of Medical Genetics (ACMG) guidelines, it uses enzymatic assay for high accuracy, supporting biochemistry screening. This test is essential for diagnosis, counseling, and improving outcomes in pediatrics.
Other Names: Hex B Activity Test, Sandhoff Disease Enzyme Assay.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic reliability.
Historical Milestone: Enzyme testing for Sandhoff began in the 1970s with research by Sandhoff, who linked hexosaminidase B deficiency to the disease. Enzymatic assay advancements in the 1980s by Sigma-Aldrich improved detection, surpassing earlier qualitative methods.
Purpose: Measures hexosaminidase B activity to diagnose Sandhoff disease, guides genetic counseling, and evaluates patients with seizures, aiming to manage symptoms.
Test Parameters: Hexosaminidase B activity
Pretest Condition: No special preparation required. Collect whole blood or fibroblasts. Report family history of neurological disorders.
Specimen: Whole Blood (EDTA, 3-5 mL), Fibroblasts (sterile culture, ~1 cma³); 4 mL whole blood in Na Heparin tube. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not recommended
Medical History: Document neurological decline or seizures. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., neurodegeneration), and sample collection risks.
Procedural Considerations: Uses enzymatic assay to measure activity, requiring labs with spectrophotometers. Results available in 5-7 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample hemolysis or delay can affect results. Medications may not affect results but require correlation.
Clinical Significance: Low activity confirms Sandhoff disease, guiding counseling. Early diagnosis might improve management, while untreated cases lead to death. Normal results may require genetic tests.
Specialist Consultation: Consult a genetic counselor or neurologist for interpretation.
Additional Supporting Tests: HEXB mutation test, MRI, or enzyme panel to confirm diagnosis.
Test Limitations: Specific to hexosaminidase B; correlation with symptoms needed. False negatives possible with atypical cases.
References: ACMG Guidelines, 2023; Journal of Biological Chemistry, Sandhoff K, 2022.
